Contact UsInvestorsCareersMediaScienceContact Us
HomeProductsPrescription MedicinesCresemba

This page is intended as reference information for the general public.

Cresemba® (isavuconazole)

What is Cresemba and what is it used for?

Cresemba is an antifungal medicine that works by blocking the production of a key component of the cell membrane of fungi. This weakens the membrane, therefore preventing fungal cell growth.

Cresemba is available as capsules and in an injectable form. In adults (aged 18 and over), it can be used to treat:

  • invasive aspergillosis

  • mucormycosis in patients for whom amphotericin B is inappropriate.

These fungal infections may occur in patients being treated for blood cancers, transplant recipients and patients in intensive care units. They are challenging to treat and have a high mortality rate.

The medicine can only be obtained with a prescription.


Reference information

The European Medicines Agency (EMA) is a decentralised agency of the European Union (EU). The Agency is responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies for use in the EU. See EMA guidance on Cresemba.

Medicines in Northern Ireland fall under the remit of the European Medicines Agency (EMA) whilst medicines in Great Britain (England, Scotland and Wales) fall under the remit of the Medicines and Healthcare products Regulatory Agency (MHRA) since the UK left the European Union. These agencies are responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies.

If you would like to see the Summary of Product Characteristics (SPC) or Patient Information Leaflet (PIL) for Cresemba, please follow these links:

Great Britain
Cresemba (isavuconazole)

Northern Ireland
Cresemba (isavuconazole)

Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professional for specific, health-related advice and support.

If you are concerned about a side-effect it can be reported directly via the Coronavirus Yellow Card reporting site or search for MHRA Yellow Card in the Google Play or Apple App Store. When completing a report please include the vaccine brand and batch/lot number if available.

PP-CRB-GBR-1823 / February 2023
Science Products Responsibility PartnershipsCareers Privacy Statement Terms of Use Contact UsSitemap Copyright © 2017-2024 Pfizer Limited. PP-UNP-GBR-8108 / January 2024. All rights reserved. Registered in England and Wales No. 526209. Registered office: Ramsgate Road, Sandwich, Kent CT13 9NJ. VAT No. GB201048427. This website is intended for the general public in the UK.